No deleterious effect of low dose methotrexate on titanium implant osseointegration in a rabbit model

Carvas, João Miguel; Pereira, Rosa Maria Rodrigues; Bonfá, Eloísa; Silveira, Celey Aparecida; Lima, Luiz Lapa; Caparbo, Valéria F.; Mello, Suzana Beatriz Verissímo de

doi:10.1590/s1807-59322011000600023

Cited by 8 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Carvas et al . [ 16 ] evaluated the osseointegratiom process in a rabbit model during an 18-week period. Groups of 6-8 rabbits were treated with saline, methotrexate, glucocorticoid, or methotrexate plus glucocorticoid and received implants after 6 weeks.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Effect of Low-Dose Methotrexate on Osseointegration of Implants: A Biomechanical Study on Dogs

Tavakoli¹,

Yaghini²,

Abed³

et al. 2018

TODENTJ

View full text Add to dashboard Cite

Background:Methotrexate (MTX) is an immunosuppressive drug, widely used in inflammatory disturbances including rheumatoid arthritis. However, there is no consensus regarding the effect of MTX on implant osseointegration.Objective:The purpose of this experimental study was to investigate the effect of low dose MTX on Bone-Implant Contact (BIC) of dogs.Methods:Six mandibular premolar teeth (bilateral) of 8 mature dogs were extracted. After 3 months of healing, 6 implants (bone level, resorbable blast media surface) were inserted into the mandible of each dog (3 in each side). Dogs were randomly divided into a study group (receiving 2.5 mg/week MTX orally, 3 times per week for 4 weeks) and a control group each containing 4 dogs. In the 1st week, postoperative BIC was evaluated in 4 dogs, two from each group. In the 4th week, reverse torque and BIC were evaluated in the remaining 4 dogs. Data were analyzed with two-way ANOVA test for 95% confidence interval.Results:The reverse torque test of the 4th week, showed a satisfying osseointegration. Histopathologic evaluation revealed that the BIC was significantly higher in the control group in comparison to the MTX group in the 1st and 4th week. In addition, the BIC of both groups were significantly increased in the 4th week in comparison to the 1st week in both groups.Conclusion:MTX has the potential to interfere with osseointegration process.

show abstract

Section: Discussionmentioning

confidence: 99%

“…However, Carvas et al . found no deleterious effect of MTX on osseointegration of implants inserted in the tibia of a rabbit model [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Effect of Low-Dose Methotrexate on Osseointegration of Implants: A Biomechanical Study on Dogs

Tavakoli¹,

Yaghini²,

Abed³

et al. 2018

TODENTJ

View full text Add to dashboard Cite

show abstract

“…In a study using a canine model, a low-dose MTX reduced bone-to-implant contact (BIC), although osseointegration of inserted implant was acceptable (Tavakoli et al, 2018). On the other hand, another study demonstrated that cortical thickness, total bone area and BIC were not significantly different between the control and MTX groups in a rabbit model (Carvas et al, 2011). In a retrospective case series analyzing implant treatment in patients with RA and connective tissue disease (CTD), 13 implants were inserted in patients receiving MTX, and they all survived (Weinlander et al, 2010) (Table 4).…”

Section: Methotrexatementioning

confidence: 99%

Effect of agents affecting bone homeostasis on short‐ and long‐term implant failure

Jung,

Ryu,

Shim

et al. 2023

Clinical Oral Implants Res

View full text Add to dashboard Cite

ObjectivesTo review the current evidence on the relationship between agents that affect bone homeostasis and dental implant failures.Materials and MethodsElectronic searches for bisphosphonates, denosumab, methotrexate, corticosteroids, romosozumab, sunitinib, and bevacizumab were performed using PubMed, MEDLINE (OVID), EMBASE (OVID), Cochrane Central Register of Controlled Trials (Cochrane Library), Cochrane Oral Health Group Trials Register (Cochrane Library) and Web of Science (Thomson Reuters). Manual searches were also conducted to complement the digital searches for recent issues.ResultsPrevious publications suggested that bisphosphonates do not compromise the survival of dental implants. However, one study documented an increased risk of implant failure in patients who had received high‐dose of intravenous bisphosphonate therapy after implant rehabilitation. There has been an issue of MRONJ around implants in patients who have successfully received implant therapy before and after antiresorptive therapy, leading to late implant failure. Despite evidence on the detrimental effects of denosumab, methotrexate and corticosteroids on bone metabolism, their role in implant survival is not conclusive.ConclusionsAt present, there is insufficient evidence to establish a potential connection between agents that affects bone homeostasis and implant failure. However, some studies have reported negative results for implant therapy. In addition, implant‐related sequestration in patients who received anti‐resorptive therapy, despite of successful osseointegration, is also noticeable. Although limited studies are available at present, clinicians should still carefully consider the potential hazards and take appropriate precautions to minimize the risks associated with the medications and implant therapy.

show abstract

“…However, to the best of our knowledge there are no published data concerning the impact of immunosuppressive drug agents, used for autoimmune disease treatment, on dental implant surgery in humans. The only studies found referred to animals and suggest controversial results 68,69 .…”

Section: Immunosuppressive Drugsmentioning

confidence: 99%

Dental implants in patients with oral autoimmune diseases

Tounta¹

2019

JRPMS

View full text Add to dashboard Cite

Oral mucosal autoimmune diseases include a variety of disorders, like oral lichen planus (OLP), pemphigus vulgaris (PV), mucous membrane (MMP) and bullous pemphigoid (BP), epidermolysis bullosa acquisita (EBA), systemic lupus erythematosus (SLE) and Sjögren syndrome (SS) and can cause painful erosions, blisters and ulceration at the oral epithelium. Such diseases complicate dental hygiene and can lead to tooth loss. When natural teeth are missing, dental implants can improve quality of life for these patients. Osseointegration is necessary for dental implant success and is not contraindicated for patients with oral mucosal autoimmune diseases. However, the clinical dentist must consider the possible impact of oral autoimmune diseases on the oral epithelium that might affect implant success, also due to the difficulty of everyday oral hygiene, leading to bone absorption around the implant. Moreover, medication approved for the therapy of such diseases, such as corticosteroids, immunosuppressants and non-steroidal anti-inflammatory drugs (NSAIDs) could provoke osseointegration, as it compromises bone quality and affects the patient's general health. However, the impact of these drugs on implant surgery depends on dose and duration of the drug and usually dental implantation is possible.

show abstract

No deleterious effect of low dose methotrexate on titanium implant osseointegration in a rabbit model

Cited by 8 publications

References 26 publications

Evaluation of Effect of Low-Dose Methotrexate on Osseointegration of Implants: A Biomechanical Study on Dogs

Evaluation of Effect of Low-Dose Methotrexate on Osseointegration of Implants: A Biomechanical Study on Dogs

Effect of agents affecting bone homeostasis on short‐ and long‐term implant failure

Dental implants in patients with oral autoimmune diseases

Contact Info

Product

Resources

About